Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):911–913. doi: 10.1038/bjc.1994.175

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

E Tartour 1, T Dorval 1, V Mosseri 1, L Deneux 1, C Mathiot 1, H Brailly 1, F Montero 1, I Joyeux 1, P Pouillart 1, W H Fridman 1
PMCID: PMC1968905  PMID: 8180022

Abstract

Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.

Full text

PDF
911

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Le J. M., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol. 1989 Dec 1;143(11):3517–3523. [PubMed] [Google Scholar]
  2. Balch C. M., Soong S. J., Murad T. M., Smith J. W., Maddox W. A., Durant J. R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983 Feb;1(2):126–134. doi: 10.1200/JCO.1983.1.2.126. [DOI] [PubMed] [Google Scholar]
  3. Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
  4. Broom J., Heys S. D., Whiting P. H., Park K. G., Strachan A., Rothnie I., Franks C. R., Eremin O. Interleukin 2 therapy in cancer: identification of responders. Br J Cancer. 1992 Dec;66(6):1185–1187. doi: 10.1038/bjc.1992.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dillman R. O., Church C., Oldham R. K., West W. H., Schwartzberg L., Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer. 1993 Apr 1;71(7):2358–2370. doi: 10.1002/1097-0142(19930401)71:7<2358::aid-cncr2820710730>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  6. Koh H. K. Cutaneous melanoma. N Engl J Med. 1991 Jul 18;325(3):171–182. doi: 10.1056/NEJM199107183250306. [DOI] [PubMed] [Google Scholar]
  7. Lee J. D., Sievers T. M., Skotzko M., Chandler C. F., Morton D. L., McBride W. H., Economou J. S. Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res. 1992 Jun;11(3):161–166. [PubMed] [Google Scholar]
  8. Lu C., Kerbel R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993 Mar;120(5):1281–1288. doi: 10.1083/jcb.120.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lu C., Vickers M. F., Kerbel R. S. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9215–9219. doi: 10.1073/pnas.89.19.9215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Luger T. A., Krutmann J., Kirnbauer R., Urbanski A., Schwarz T., Klappacher G., Köck A., Micksche M., Malejczyk J., Schauer E. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol. 1989 Aug 15;143(4):1206–1209. [PubMed] [Google Scholar]
  11. Marincola F. M., Venzon D., White D., Rubin J. T., Lotze M. T., Simonis T. B., Balkissoon J., Rosenberg S. A., Parkinson D. R. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res. 1992 Dec 1;52(23):6561–6566. [PubMed] [Google Scholar]
  12. Markowitz J. S., Cosimi L. A., Carey R. W., Kang S., Padyk C., Sober A. J., Cosimi A. B. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg. 1991 Jun;126(6):703–708. doi: 10.1001/archsurg.1991.01410300045006. [DOI] [PubMed] [Google Scholar]
  13. Mathé G. Is the AIDS virus responsible for the disease? Biomed Pharmacother. 1992;46(1):1–2. doi: 10.1016/0753-3322(92)90062-c. [DOI] [PubMed] [Google Scholar]
  14. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989 Jul 3;250(2):607–610. doi: 10.1016/0014-5793(89)80805-1. [DOI] [PubMed] [Google Scholar]
  15. Mulé J. J., McIntosh J. K., Jablons D. M., Rosenberg S. A. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990 Mar 1;171(3):629–636. doi: 10.1084/jem.171.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Porgador A., Tzehoval E., Katz A., Vadai E., Revel M., Feldman M., Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992 Jul 1;52(13):3679–3686. [PubMed] [Google Scholar]
  17. Zhou D., Munster A., Winchurch R. A. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-beta. FASEB J. 1991 Aug;5(11):2582–2585. doi: 10.1096/fasebj.5.11.1868982. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES